相关实验视频

Updated: May 16, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

神经内分泌瘤中的α放射性疗法:当前的景观和RYZ101的聚光灯

Udhayvir S Grewal^1,2, Olumide B Gbolahan^3,4, Amol M Takalkar^4,5

¹Division of Hematology, Oncology and Bone and Marrow Transplantation, University of Iowa Health Care, Iowa City, IA, USA.

Future oncology (London, England)

|March 31, 2025

概括

像RYZ101这样的α放射性对象疗法 (RLT) 药物对神经内分泌瘤 (NETs) 显示出前景. 这种先进的RLT比βRLT提供了潜在的优势,目前正在进行的试验评估其有效性和安全性.

科学领域:

在瘤学瘤学.
核医学就是核医学.
放射性药物疗法是一种放射性药物疗法.

背景情况:

神经内分泌瘤 (NETs) 的治疗已经显著扩大,包括索马托斯塔丁类似物 (SSA),向疗法,化疗和放射性连接体疗法 (RLT) 等选择.
贝塔发射RLT (例如,177Lu-DOTATATE) 已被批准用于NET,但其充分的治疗潜力尚未实现.
与β RLT相比,α RLT药物呈现了一种新的方法,具有更高的疗效和减少副作用的潜力.

研究的目的:

审查目前的RLT环境,并突出阿尔法RLT代理的潜力,特别是RYZ101.1.
讨论作用机制,临床前和临床数据,以及正在进行的在NET患者中研究RYZ101的试验.
探索alpha RLT在增强NET治疗策略中的未来前景.

主要方法:

对阿尔法RLT药物的现有临床前和临床数据的审查,重点是RYZ101 (225Ac-DOTATATE).
对正在进行的ACTION-1阶段1b/3试验进行分析,将RYZ101与晚期胃肠道胰腺 NET 的标准护理进行比较.
讨论阿尔法RLT相对于βRLT的比较优势 (例如,DNA损伤,向细胞毒性).

主要成果:

临床前和临床数据表明,在NET患者中,RYZ101的安全性和疗效概况有利.
RYZ101显示了诱导更复杂的DNA断裂和向细胞毒性的潜力.
ACTION-1试验正在积极评估RYZ101在177Lu-SSA治疗后的高级NET患者中.

结论:

阿尔法RLT药物,以RYZ101为例,代表了NET疗法的有希望的进步.
由于其向细胞毒性和DNA损伤能力的机制,RYZ101提供了潜在的治疗优势.
进一步的调查和正在进行的试验的长期数据对于充分确定alpha RLT在NET管理中的作用至关重要.

关键词:

225Ac-DOTATATE的使用方法神经内分泌新生体的神经内分泌新生体阿尔法无线电配体疗法受体放射性核酸疗法是一种受体疗法.索马托斯坦因子受体向向有针对性的阿尔法疗法

更多相关视频

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Published on: June 23, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Transducer Mechanism: Nuclear Receptors

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes: